To retrospectively evaluate safety and efficacy of long-term treatment with Cyclosporine A (CSA) in patients with systemic lupus erythematosus (SLE) poorly responsive to treatment with corticosteroids (CCS) and/or conventional disease-modifying anti-rheumatic drugs (DMARDs), SLE patients who had received CSA-based induction and maintenance regimens according to disease activity were recorded. Efficacy was assessed using the SLE Disease Activity Index (SLEDAI) and laboratory analyses. Forty SLE patients [including 18 with lupus nephritis, 11 with neurological involvement and 7 with overlap syndromes (4 Sjögren's syndrome, 2 myasthenia gravis and 1 Behçet's disease)] were recorded. According to baseline SLEDAI, 30 patients had severe and 10 moderate SLE. Mean SLEDAI scores and relevant laboratory values significantly reduced from baseline (22±10 vs 5±6; P < 0.002) during the follow-up period (8±2 years; range 1-15). Twenty-three (57.5%) patients achieved excellent (improvement in the range 70-100%) response to treatment (10 of whom were subsequently maintained on CSA monotherapy), 14 (35%) had good/fair (improvement in the range 25-69%) response and 3 (7.5%) had to interrupt therapy (including CSA) for disease worsening. Mild and transient adverse events occurred in 15 (37%) patients, including hypertrichosis (17.5%), gum hypertrophy (17.5%) hypertension (12.5%), abdominal pain (7.5%), and dyslipidemia (5%), but treatment interruption was not required. Low-dose CSA together with other drugs is effective to induce, or as monotherapy to maintain, long-term (at least 2 years) remission, and is generally well tolerated in patients with moderate or severe SLE poorly responsive to CCS and/or conventional DMARDs. Furthermore, the favourable effect of CSA treatment may allow to spare more cytotoxic drugs. Copyright © by BIOLIFE, s.a.s.

Cyclosporine A in the long-term management of systemic lupus erythematosus / Germano, Valentina; PICCHIANTI DIAMANTI, Andrea; Ferlito, Claudia; Podesta', Edoardo; S., Salemi; D'Amelio, Raffaele; Raffaele, D'Amelio; Lagana', Bruno. - In: JOURNAL OF BIOLOGICAL REGULATORS & HOMEOSTATIC AGENTS. - ISSN 0393-974X. - STAMPA. - 25:3(2011), pp. 397-403.

Cyclosporine A in the long-term management of systemic lupus erythematosus

GERMANO, VALENTINA;PICCHIANTI DIAMANTI, Andrea;FERLITO, CLAUDIA;PODESTA', EDOARDO;D'AMELIO, Raffaele;LAGANA', Bruno
2011

Abstract

To retrospectively evaluate safety and efficacy of long-term treatment with Cyclosporine A (CSA) in patients with systemic lupus erythematosus (SLE) poorly responsive to treatment with corticosteroids (CCS) and/or conventional disease-modifying anti-rheumatic drugs (DMARDs), SLE patients who had received CSA-based induction and maintenance regimens according to disease activity were recorded. Efficacy was assessed using the SLE Disease Activity Index (SLEDAI) and laboratory analyses. Forty SLE patients [including 18 with lupus nephritis, 11 with neurological involvement and 7 with overlap syndromes (4 Sjögren's syndrome, 2 myasthenia gravis and 1 Behçet's disease)] were recorded. According to baseline SLEDAI, 30 patients had severe and 10 moderate SLE. Mean SLEDAI scores and relevant laboratory values significantly reduced from baseline (22±10 vs 5±6; P < 0.002) during the follow-up period (8±2 years; range 1-15). Twenty-three (57.5%) patients achieved excellent (improvement in the range 70-100%) response to treatment (10 of whom were subsequently maintained on CSA monotherapy), 14 (35%) had good/fair (improvement in the range 25-69%) response and 3 (7.5%) had to interrupt therapy (including CSA) for disease worsening. Mild and transient adverse events occurred in 15 (37%) patients, including hypertrichosis (17.5%), gum hypertrophy (17.5%) hypertension (12.5%), abdominal pain (7.5%), and dyslipidemia (5%), but treatment interruption was not required. Low-dose CSA together with other drugs is effective to induce, or as monotherapy to maintain, long-term (at least 2 years) remission, and is generally well tolerated in patients with moderate or severe SLE poorly responsive to CCS and/or conventional DMARDs. Furthermore, the favourable effect of CSA treatment may allow to spare more cytotoxic drugs. Copyright © by BIOLIFE, s.a.s.
2011
cyclosporine a; systemic lupus erythematosus disease activity index
01 Pubblicazione su rivista::01a Articolo in rivista
Cyclosporine A in the long-term management of systemic lupus erythematosus / Germano, Valentina; PICCHIANTI DIAMANTI, Andrea; Ferlito, Claudia; Podesta', Edoardo; S., Salemi; D'Amelio, Raffaele; Raffaele, D'Amelio; Lagana', Bruno. - In: JOURNAL OF BIOLOGICAL REGULATORS & HOMEOSTATIC AGENTS. - ISSN 0393-974X. - STAMPA. - 25:3(2011), pp. 397-403.
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/427779
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 35
  • ???jsp.display-item.citation.isi??? 31
social impact